Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $137.00 |
High: | $N/A |
Low: | $N/A |
Volume: | 2,500 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $N/A | $137.00 | $N/A | $N/A | 2,500 | 07-31-2018 |
$ | $136.80 | $137.00 | $137.00 | $136.75 | 1,009,197 | 07-30-2018 |
$ | $136.825 | $136.80 | $136.85 | $136.60 | 1,440,287 | 07-27-2018 |
$ | $136.80 | $136.75 | $136.90 | $136.75 | 817,047 | 07-26-2018 |
$ | $136.80 | $136.80 | $136.925 | $136.75 | 898,896 | 07-25-2018 |
$ | $136.90 | $136.80 | $136.90 | $136.65 | 994,399 | 07-24-2018 |
$ | $136.85 | $136.80 | $136.95 | $136.80 | 493,415 | 07-23-2018 |
$ | $136.90 | $136.95 | $136.95 | $136.75 | 894,530 | 07-20-2018 |
$ | $136.85 | $136.90 | $136.95 | $136.85 | 595,013 | 07-19-2018 |
$ | $136.85 | $136.80 | $136.90 | $136.80 | 272,434 | 07-18-2018 |
$ | $136.70 | $136.85 | $136.90 | $136.70 | 348,356 | 07-17-2018 |
$ | $136.70 | $136.70 | $136.80 | $136.70 | 801,135 | 07-16-2018 |
$ | $136.675 | $136.70 | $136.70 | $136.65 | 301,534 | 07-13-2018 |
$ | $136.70 | $136.675 | $136.70 | $136.65 | 346,307 | 07-12-2018 |
$ | $136.65 | $136.70 | $136.70 | $136.60 | 344,785 | 07-11-2018 |
$ | $136.65 | $136.65 | $136.70 | $136.60 | 552,911 | 07-10-2018 |
$ | $136.70 | $136.60 | $136.70 | $136.60 | 920,861 | 07-09-2018 |
$ | $136.75 | $136.65 | $136.85 | $136.60 | 859,001 | 07-06-2018 |
$ | $136.65 | $136.80 | $136.80 | $136.60 | 534,424 | 07-05-2018 |
$ | $136.65 | $136.65 | $136.80 | $136.60 | 595,741 | 07-03-2018 |
News, Short Squeeze, Breakout and More Instantly...
Foundation Medicine Inc. Company Name:
FMI Stock Symbol:
NASDAQ Market:
Foundation Medicine Inc. Website:
The global athletic footwear market was valued at US$ 82.56 Billion in 2022 and is expected to expand at a CAGR of 4.8% during the forecast period, ranging from 2023 to 2033
SAN DIEGO, April 20, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the addition of three independent directors to it...